Could placental stem cell vesicles ease COVID-19?
NCT ID NCT07664696
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests a single IV dose of placental stem cell vesicles (XoGlo Pro) against placebo in 64 adults with mild to moderate COVID-19. The main goal is safety, with a secondary focus on how quickly symptoms resolve. Researchers aim to see if these tiny cell particles can calm the immune response and speed recovery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- placental stem cell vesicles (XoGlo Pro)
- What this could lead to
- If it works, this could offer a new way to reduce COVID-19 symptoms and speed up recovery without needing long-term medication.
- What could go wrong
- This is an early phase trial with only 64 people, so results may not apply broadly. The treatment could cause side effects or prove no better than placebo.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Five years on: how does long COVID evolve?
- Can a targeted pill tame severe COVID-19?
- Can an organic compound tame COVID-19 in High-Risk patients?
- Could exercise retrain the heart in long COVID?
- Can a new drug shield lungs from COVID-19's worst damage?
- Can paxlovid hold the line against severe COVID-19 outside the lab?